BMY Stock Recent News

Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion piece published by Stat News on Monday.

The first report for U.S. gross domestic product (GDP) came in at −0.3% as the economy contracted for the first time in three years.

When markets get choppy, smart investors often seek refuge in pharmaceutical stocks. These companies typically offer consistent cash flows, essential products, and solid dividends regardless of economic conditions.

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Earnings season offers opportunities to buy undervalued blue-chip stocks like Verizon and Bristol Myers Squibb, both yielding 5-7% and trading below historical PE ratios. Verizon's growth in 5G, broadband, and prepaid services, combined with cost optimization, supports its 6.5% yield and potential for market-beating returns. Bristol Myers Squibb's focus on innovative medicines, cost savings, and a strong balance sheet underpins its 5.2% yield and long-term growth potential.

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts.

Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised positively, beating estimates by 20%. BMS upgraded its 2025 guidance a bit too, reducing expected revenue shrinkage to 4.1% and raising non-GAAP EPS expectations by 2.24%.

Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth portfolio is thriving, with significant YoY increases in key drugs, offsetting declines in its legacy products. BMY's consistent dividend growth and strong profitability make it an attractive income investment, especially as the Fed reduces rates.